InVitae saw the highest growth of 0.66% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of InVitae’s patent filings and grants. Buy the databook here.
InVitae has been focused on protecting inventions in Australia(AU) with two publications in Q2 2024
The Australia(AU) Patent Office dominates the patent filings and grants with nearly 20% filings and 50% grants. The United States(US), World Intellectual Property Organization(WIPO), Australia(AU), and European Patent Office(EPO) patent Office are among the top ten patent offices where InVitae is filings its patents. Among the top granted patent authorities, InVitae has 50% of its grants in Australia(AU) and 50% in European Patent Office(EPO).
Chinese University of Hong Kong could be the strongest competitor for InVitae
Patents related to genomics and machine learning lead InVitae's portfolio
InVitae has the highest number of patents in genomics followed by, machine learning and healthtech. For genomics, nearly 21% of patents were filed and 25% of patents were granted in Q2 2024.
Machine learning related patents lead InVitae portfolio followed by autonomous driving, and communications
InVitae has highest number of patents in machine learning followed by autonomous driving, communications, enterprise applications, and mos micro (mpu, mcu & dsp). For machine learning, nearly 33% of patents were filed and 40% of patents were granted in Q2 2024.
For comprehensive analysis of InVitae's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.